Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Jeffrey S. Weber, MD, PhD, discusses the phase III EORTC1325/KEYNOTE-054 trial, which looked at adjuvant pembrolizumab in patients with stage III melanoma.

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.